Practical vs Recent Clinical Trial Use Of Dalbavancin - Scorecard - MDSpire

Practical vs Recent Clinical Trial Use Of Dalbavancin

  • By

  • Sarah A. Uhm

  • Bryan T. Alexander

  • Elizabeth R. Lyden

  • Nicolas Cortes-Penfield

  • Harlan R. Sayles

  • Sara F. Azimi

  • Mackenzie R. Keintz

  • Molly M. Miller

  • Mark E. Rupp

  • Jasmine R. Marcelin

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Dalbavancin in Clinical Trials Versus Real-World Applications

At a Glance

CategoryDetail
Condition
Key MechanismsLong-acting intravenous lipoglycopeptide (source needed).
Target Population
Care Setting

Key Highlights

  • Remove unsupported claims about clinical implications.

Guideline-Based Recommendations

Diagnosis

    Management

    • R
    • e
    • m
    • o
    • v
    • e
    • u
    • n
    • s
    • u
    • p
    • p
    • o
    • r
    • t
    • e
    • d
    • r
    • e
    • c
    • o
    • m
    • m
    • e
    • n
    • d
    • a
    • t
    • i
    • o
    • n
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults treated at Nebraska Medicine from January 1, 2019, to December 31, 2024.

        Dalbavancin use influenced by insurance approval and cost.

        Clinical Best Practices

        • Ensure practices are directly supported by the source.

        Related Resources & Content

        Original Source(s)

        Practical vs Recent Clinical Trial Use Of Dalbavancin

        • by Sarah A. Uhm, Bryan T. Alexander, Elizabeth R. Lyden, Nicolas Cortes-Penfield, Harlan R. Sayles, Sara F. Azimi, Mackenzie R. Keintz, Molly M. Miller, Mark E. Rupp, Jasmine R. Marcelin

        • June 3, 2026

        Related Content

        CD4/CD8 ratio is associated with structural reorganization of vaccine-induced immune responses in people living with HIV

        Genomic diagnosis and multisystem phenotyping in pediatric congenital analbuminemia: clinical, coagulation, and immune signatures

        FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

        Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.